Equities research analysts at Deutsche Bank Aktiengesellschaft started coverage on shares of BioNTech (NASDAQ:BNTX) in a report released on Friday, The Fly reports. The brokerage set a "hold" rating on the stock.
Other research analysts also recently issued research reports about the company. Berenberg Bank set a $400.00 price objective on BioNTech in a research note on Tuesday, October 5th. HC Wainwright reaffirmed a "hold" rating and issued a $330.00 price objective on shares of BioNTech in a research note on Tuesday, October 5th. UBS Group set a $300.00 price objective on BioNTech in a research note on Thursday, September 23rd. Zacks Investment Research downgraded shares of BioNTech from a "buy" rating to a "hold" rating in a research report on Wednesday, October 13th. Finally, Bryan, Garnier & Co set a $359.00 target price on shares of BioNTech in a research report on Tuesday, October 5th. One analyst has rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, BioNTech presently has a consensus rating of "Hold" and an average price target of $255.36.
Shares of NASDAQ BNTX opened at $286.36 on Friday. The company has a current ratio of 2.67, a quick ratio of 2.57 and a debt-to-equity ratio of 0.04. The company has a market cap of $69.45 billion, a price-to-earnings ratio of 14.98 and a beta of -1.59. BioNTech has a 12 month low of $75.35 and a 12 month high of $464.00. The stock has a 50-day moving average price of $321.80 and a two-hundred day moving average price of $253.24.
BioNTech (NASDAQ:BNTX) last issued its earnings results on Sunday, August 8th. The company reported $10.77 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $8.35 by $2.42. The firm had revenue of $5.31 billion during the quarter, compared to the consensus estimate of $3.27 billion. BioNTech had a return on equity of 159.73% and a net margin of 52.48%. The business's quarterly revenue was up 12599.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.38) earnings per share. On average, sell-side analysts predict that BioNTech will post 37.71 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BNTX. Fosun International Ltd purchased a new stake in BioNTech in the 2nd quarter valued at $353,904,000. Coatue Management LLC raised its position in BioNTech by 261.7% in the 2nd quarter. Coatue Management LLC now owns 1,236,317 shares of the company's stock valued at $276,787,000 after buying an additional 894,471 shares during the last quarter. BlackRock Inc. raised its position in BioNTech by 99.4% in the 2nd quarter. BlackRock Inc. now owns 1,481,390 shares of the company's stock valued at $331,654,000 after buying an additional 738,532 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in BioNTech by 31.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,074,906 shares of the company's stock valued at $226,559,000 after buying an additional 500,085 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in BioNTech in the 2nd quarter valued at $73,570,000. 14.49% of the stock is owned by institutional investors and hedge funds.
BioNTech Company Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors.
See Also: Green Investing
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here